iproniazid has been researched along with amantadine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Ho, IK; Iwamoto, ET; Khanna, S; Loh, HH; Shen, F; Way, EL | 1 |
| Korduba, CA; Symchowicz, S; Veals, J | 1 |
| Chemuturi, NV; Donovan, MD | 1 |
1 review(s) available for iproniazid and amantadine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for iproniazid and amantadine
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Precipitation of abstinence-like syndrome in morphine-dependent mice by pargyline.
Topics: Amantadine; Amphetamine; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hydrazines; Iproniazid; Male; Mice; Mice, Inbred ICR; Morphine Dependence; Motor Activity; Naloxone; Pargyline; Substance Withdrawal Syndrome; Time Factors; Tranylcypromine | 1976 |
The effect of amantadine on radiolabeled biogenic amines in the rat brain.
Topics: Amantadine; Animals; Biogenic Amines; Brain; Brain Chemistry; Carbon Isotopes; Chromatography, Paper; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Injections; Iproniazid; Male; Monoamine Oxidase; Norepinephrine; Rats; Serotonin; Synaptosomes; Tritium | 1973 |
Metabolism of dopamine by the nasal mucosa.
Topics: 2,4-Dinitrophenol; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; Biological Availability; Cattle; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Immunohistochemistry; Iproniazid; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nasal Mucosa; Organ Culture Techniques; Piperazines; Spectrophotometry, Ultraviolet | 2006 |